Analyst Price Targets — OMER
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 8, 2026 11:05 am | Brandon Folkes | H.C. Wainwright | $40.00 | $14.09 | TheFly | Omeros price target raised to $40 from $20 at H.C. Wainwright |
| October 15, 2025 2:53 pm | — | H.C. Wainwright | $20.00 | $10.38 | TheFly | Omeros price target raised to $20 from $9 at H.C. Wainwright |
| June 27, 2025 1:35 pm | Brandon Folkes | H.C. Wainwright | $9.00 | $3.20 | TheFly | Omeros submission adds another 2026 catalyst, says H.C. Wainwright |
| December 8, 2022 8:30 am | — | UBS | $2.00 | $2.03 | Benzinga | UBS Downgrades Omeros to Neutral, Lowers Price Target to $2 |
Latest News for OMER
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros' OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such…
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have…
Omeros Corporation (NASDAQ: OMER - Get Free Report) CAO David Borges sold 30,000 shares of the company's stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the SEC, which is available at this
Omeros Corporation (NASDAQ: OMER - Get Free Report) shares dropped 5.8% on Thursday following insider selling activity. The stock traded as low as $12.42 and last traded at $12.3160. Approximately 244,474 shares traded hands during trading, a decline of 93% from the average daily volume of 3,314,114 shares. The stock had previously closed at $13.08. Specifically,
Omeros (NASDAQ: OMER) outlined its U.S. launch plans for Yarcomlia (narsoplimab) and discussed clinical data, reimbursement preparations, and supply expectations following the drug's FDA approval on December 23, 2025, during a company conference call led by Chairman and CEO Dr. Gregory Demopulos. FDA approval and scope of the indication Demopulos said Yarcomlia is the first and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OMER.
U.S. House Trading
No House trades found for OMER.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.